- Marketwired via Yahoo! FinanceMay 02 09:00 AM
GeoVax Labs, Inc. , a biotechnology company specializing in developing human vaccines, presented today at the conference Bridging the Sciences: Zika Virus, held at the Emory Conference Center in Atlanta, ...
- Science DailyMay 03 12:16 PM
The clinical phase I trial of a potential vaccine against the dreaded Ebola virus has been successfully completed at four partner sites in Africa and Europe. The safety of the tested vaccine 'rVSV-ZEBOV', which induces persistent antibodies against the virus, has been confirmed by researchers.
- MarketwireMay 02 09:39 AM
ATLANTA, GA--(Marketwired - May 2, 2016) - GeoVax Labs, Inc. ( OTCQB : GOVX ), a biotechnology company specializing in developing human vaccines, presented today at the conference Bridging the Sciences: Zika Virus , held at the Emory Conference Center in Atlanta, Georgia.
GeoVax Provides Update on Zika Vaccine Program - Marketwire
- Entertainment WeeklyApr 10 06:46 PM
Bess comes up with a plan to release a group of Nigerian school girls from captivity
- Marketwired via Yahoo! FinanceApr 18 06:00 AM
GeoVax Labs, Inc. , a biotechnology company developing human vaccines, provided an update today on its program to develop a safe and effective vaccine to prevent Zika virus infection in humans. No approved ...
- Marketwired via Yahoo! FinanceMay 04 06:00 AM
GeoVax Labs, Inc. , a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2016.
- Deutsche WelleApr 22 12:54 PM
- News-Medical-NetMay 03 10:26 PM
"The results for tolerability, safety, and the immune response to the vaccine candidate are very promising," explains Prof Marylyn Addo. The antibodies which developed against the virus were still detectable after six months. Addo is convinced, "With this, a single vaccine could provide lasting protection against Ebola." The infectious disease specialist, who works for the German Center for ...
Two Ebola vaccine candidates show promise in cli... - News-Medical-Net
- EurekAlert!Apr 19 10:43 AM
( NIH/National Institute of Allergy and Infectious Diseases ) An immunization regimen using two Ebola vaccine candidates was safe, well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are described in the April 19th issue of the Journal of the American Medical Association. NIAID has supported the development and testing of...
- Journal of the American Medical AssociationApr 19 08:53 AM
This phase 1 randomized clinical trial investigated the safety and tolerability of 2 vaccines against Ebola virus: an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV) and a modified vaccinia Ankara vector vaccine encoding glycoproteins from Ebola virus, Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein (MVA-BN-Filo).
- related to marburg virus